Search
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 re...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGarenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAsenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalDeveloped by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also be...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTolperisone
go.drugbank.com/drugs/DB06264InvestigationalTolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesUdenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigationalTocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigationalLevocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine w...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAmisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalAmisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and ...
Categories: P-glycoprotein substratesElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigationalElacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It re...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates